ISPR

Business Context and Reporting Period

Company: Ispire Technology Inc. (ISPR)
Filing Type: Form 10-Q (Unaudited)
Reporting Period: Three and nine months ended March 31, 2025
Business Overview: Ispire is a holding company engaged in the research, development, and distribution of branded e-cigarettes and cannabis vaping products. Operations are conducted primarily through subsidiaries Aspire North America (cannabis) and Aspire Science (nicotine). The company recently established subsidiaries in the UAE, California, and the UK to expand logistics and sales.

Key Financial Metrics

Material Changes vs. Prior Period

• Revenue Decline: Revenue decreased 12.7% quarter-over-quarter (QoQ) and 6.3% year-over-year (YoY) for the nine-month period. The decline was driven by a $3.6 million drop in North American sales and a $0.8 million drop in Asia Pacific sales, partially offset by growth in Europe (+$10.0M for nine months) and Africa (+$5.5M for nine months).
• Increased Operating Expenses: Operating expenses rose 23.3% QoQ to $15.36 million. General and Administrative (G&A) expenses increased significantly due to a $4.9 million provision for credit losses in the quarter (totaling $13.4 million for the nine months).
• Widening Net Loss: Net loss more than doubled QoQ from $5.93 million to $10.86 million, primarily due to the credit loss provision and increased operating costs.
• Related Party Payables: Accounts payable to a related party (Shenzhen Yi Jia, a supplier owned by the CEO) increased to $77.12 million from $67.05 million at the prior fiscal year-end.

Outlook, Risks, and Management Commentary

• Regulatory Environment: The company faces significant regulatory hurdles in the U.S. nicotine market, currently limited to selling one product line (Nautilus Prime) pending FDA Premarket Tobacco Product Application (PMTA) reviews. A new PMTA for a disposable product was submitted in September 2024.
• Tariff Risks: Management highlights severe exposure to U.S. tariffs. As of May 2025, tariffs on Chinese goods are reported at 145%, while Malaysian goods face a 24% tariff (paused at 10% for 90 days). The company relies heavily on Shenzhen Yi Jia (China) for manufacturing but is leveraging its Malaysia facility for cannabis hardware to mitigate costs.
• Liquidity: The company reported a negative working capital position of $(2.15) million. Cash used in operating activities was $12.07 million for the nine months ended March 31, 2025. Management believes current cash and bank loans are sufficient for the next 12 months but may require additional financing.
• Internal Controls: Management disclosed that disclosure controls and procedures were not effective as of March 31, 2025, citing material weaknesses in recording assets from controlling stockholders, evaluating significant estimates (inventory and credit loss reserves), and a lack of comprehensive accounting policies.
• Joint Venture: The company holds a 40% interest in IKE Tech LLC (age-verification technology), which recorded a net loss of $1.02 million for the nine months ended March 31, 2025.

Investor Verification Checklist

• Credit Loss Provision: Verify the methodology and assumptions behind the $13.4 million credit loss expense recorded in the nine-month period, which significantly impacted net income.
• Related Party Transactions: Review the terms and pricing of the $77.1 million payable to Shenzhen Yi Jia (95% owned by the CEO) to ensure arm's length valuation.
• Tariff Impact: Assess the financial impact of the reported 145% tariff on Chinese imports and the sustainability of the Malaysia manufacturing advantage.
• Internal Control Remediation: Monitor the company's progress in addressing the material weaknesses in internal controls over financial reporting.
• U.S. Market Access: Track the status of the PMTA applications for nicotine products, as current U.S. sales are severely restricted.